Cogmotos, Inc.
Cogmotos is a clinical-stage company focused on developing innovative treatments for high-impact neurological diseases, starting with postoperative delirium. They utilize intranasal, direct-to-brain drug delivery technology to overcome the blood-brain barrier, enabling effective treatment options for neurological disorders. Their approach involves proprietary delivery devices and a focus on improving patient outcomes while reducing healthcare costs.
Industries
Nr. of Employees
small (1-50)
Products
Intranasal direct-to-brain drug delivery device platform
A controlled-aerosol intranasal delivery platform designed to deliver therapeutics along the olfactory route into the brain, available in clinical and commercial form factors and intended to enable delivery of molecules that otherwise do not cross the blood-brain barrier.
Kurve Intranasal Drug Delivery Platform
An intranasal drug delivery platform designed to deliver therapeutics direct-to-brain via the olfactory nerves and cribriform plate, bypassing the blood-brain barrier. Used successfully in multiple Alzheimer's clinical trials with intranasal insulin.
Cogmotos Intranasal Insulin Delivery Platform
A novel intervention combining a safe, well-studied drug (intranasal insulin) with a proprietary device to deliver insulin directly to the brain, circumventing the blood-brain barrier to tackle post-operative delirium.
Intranasal direct-to-brain drug delivery device platform
A controlled-aerosol intranasal delivery platform designed to deliver therapeutics along the olfactory route into the brain, available in clinical and commercial form factors and intended to enable delivery of molecules that otherwise do not cross the blood-brain barrier.
Kurve Intranasal Drug Delivery Platform
An intranasal drug delivery platform designed to deliver therapeutics direct-to-brain via the olfactory nerves and cribriform plate, bypassing the blood-brain barrier. Used successfully in multiple Alzheimer's clinical trials with intranasal insulin.
Cogmotos Intranasal Insulin Delivery Platform
A novel intervention combining a safe, well-studied drug (intranasal insulin) with a proprietary device to deliver insulin directly to the brain, circumventing the blood-brain barrier to tackle post-operative delirium.
Services
Coordination and conduct of clinical-stage studies and collaborations with academic medical centers to evaluate safety and efficacy of intranasal therapeutics for neurological indications.
Coordination and conduct of clinical-stage studies and collaborations with academic medical centers to evaluate safety and efficacy of intranasal therapeutics for neurological indications.
Expertise Areas
- Clinical trial management for intranasal CNS therapies
- Direct-to-brain intranasal drug delivery
- Neurology therapeutics development (postoperative delirium, Alzheimer’s, Parkinson’s)
- Drug-delivery device design for self-administration
Key Technologies
- Intranasal direct-to-brain aerosol delivery
- Olfactory/cribriform plate targeting
- Controlled turbulent-flow nasal aerosolization
- Radiolabeled imaging for deposition confirmation